U-M Breast Oncology Program benefits from televised charitable shoe sale

With thousands of shoes offered at half the manufacturer’s suggested retail price during the 17th Annual QVC Presents “FFANY Shoes on Sale®,” it was easier than ever for shoe lovers to take another step forward in the fight against breast cancer.

Supporting breast cancer research and education institutions nationwide, last year’s event selected the University of Michigan Comprehensive Cancer Center as one of the eight beneficiaries. A check in the amount of $400,000 was presented by QVC and FFANY representatives to Daniel Hayes, M.D., co-director of the breast oncology program at U-M, who accepted the donation on behalf of the organization.

“FFANY and QVC have been instrumental in supporting several avenues of research that would not have been pursued otherwise,” Hayes says. “We’ve used this support to move our research in breast cancer forward, including one of the first clinical trials with a drug directed against breast cancer stem cells. Other studies are looking at markers that can be used to personalize anti-cancer treatments, such as circulating tumor cells and inherited genetic differences that may make individual patients more or less susceptible to toxicities of our therapy.”

U-M’s Breast Oncology Program has received $3.7 million from this event since 2001.

Since its inception, QVC Presents “FFANY Shoes on Sale” has sold over 1.5 million pairs of shoes and donated more than $35 million to leading breast cancer research and education institutions.  The event’s two “Special Pink Benefactors,” the Nine West Footwear Corporation and Brown Shoe Company, donated more than $500,000 of inventory, bringing shoe shoppers such brands as AK Anne Klein, Enzo Angiolini and Bandolino as well as Via Spiga, Etienne Aigner and Carlos by Carlos Santana. Other companies that generously donated shoes included MICHAEL by Michael Kors, UGG Australia, Coach Footwear, BCBGeneration, Jessica Simpson, Vince Camuto and Calvin Klein – among many others.


Leave a Reply